AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong demand for its cancer and rare diseases medicines, after third-quarter results beat estimates.
AstraZeneca Raises Outlook on Earnings, Sales Beat
AstraZeneca AZN0.83%increase; green up pointing triangle raised its full-year guidance after third-quarter revenue and core earnings per share topped analysts’ expectations. The Anglo-Swedish pharmaceutical giant said Tuesday that it now expects its 2024 ...
Hosted on MSN16h
AstraZeneca Expands U.S. Investment PlanAstraZeneca said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
AstraZeneca's Q3 sales rose 18% YoY to $13.6 billion Adjusted EPADS hit $1.04, exceeding expectations. U.S. investment of ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
Reports Q3 revenue $13.6B, consensus $13.09B. Pascal Soriot, CEO, AstraZeneca (AZN), commenting on the results said: “Our company has ...
CAMBRIDGE, Britain — CAMBRIDGE, Britain — Astrazeneca PLC (AZN) on Tuesday reported third-quarter earnings of $1.43 billion. On a per-share basis, the Cambridge, Britain-based company said it had ...
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...
Reports Q3 revenue $13.57B, consensus $13.09B. Reports Q3 core EPS $2.08. Pascal Soriot, CEO, AstraZeneca (AZN), said: “Our company has continued on its strong growth trajectory in the first nine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback